HOME EMAIL SITE MAP   CHINESE ENGLISH
Home     About Us          Products          Manufacturing          Investor Relations          News & Events          R&D          Industry Update          Careers     
About Us
· Overview
· Corporate History
· Corporate Culture
· Industry Landscape
· Management Team
· Board of Directors
· Corporate Governance
Contact Us

Jiangbo Pharmaceuticals, Inc.(US office)
Ms. Elsa Sung, Chief Financial Officer, 1133 S. University Drive Suite 210 Plantation, Florida 33324
Telephone: (954)616-5583
Fax: 954-903-9378
Email:General Information: 
jiangbopharma@gmail.com Investor relations: crocker.coulson@ccgir.com

Address of Factory in China:
25 Haihe Road, Laiyang Economic Development Zone,Laiyang City,Yantai, Shandong,China 265200

 >> Home > About Us

1. Role of Board and Management
   
Jiangbo' business is conducted by its employees, managers and officers, under the direction of the chief executive
officer (CEO) and the oversight of the board, to enhance the long-term value of the company for its shareowners. The board of directors is elected by the shareowners to oversee management and to assure that the long-term interests of the shareowners are being served. Both the board of directors and management recognize that the long-term interests of shareowners are advanced by responsibly addressing the concerns of other stakeholders and interested parties including employees, recruits, customers, suppliers, Jiangbo communities, government officials and the public at large.

2. Functions of Board

The board of directors has 4 scheduled meetings a year at which it reviews and discusses reports by management on the performance of the company, its plans and prospects, as well as immediate issues facing the company. Directors are expected to attend all scheduled board and committee meetings. Because of the international makeup of the board, directors may attend telephonically, although, at least once annually, it is intended that the entire board conduct a centrally-located meeting, with all directors being present. In addition to its general oversight of management, the board also performs a number of specific functions, including: selecting, evaluating and compensating the CEO and overseeing CEO succession planning; providing counsel and oversight on the selection, evaluation, development and compensation of senior management; reviewing, approving and monitoring fundamental financial and business strategies and major corporate actions; assessing major risks facing the company  

3. Committees of the Board of Directors

The Board’s standing committees are the Audit and Compensation Committees.
 
Committee Membership
 
The following table shows the current membership on the standing committees:
 
Committee
 
Chair
 
Member
 
Member
Audit
 
Michael Marks
 
John (Yang) Wang
 
Feng Xiaowei
Compensation
 
Feng Xiaowei
 
John (Yang) Wang
 
Ge Jian
 
Audit Committee.
 
The Board of Directors has an Audit Committee established in accordance with section 3(a)(58) of Securities Exchange Act of 1934 (the “Exchange Act”). The Board of Directors has determined that each of the members of the Audit Committee is “independent,” as defined in the corporate governance listing standards of NASDAQ and Rule 10A-3 under the Exchange Act relating to audit committees. In addition, the Board has determined that all members of the Audit Committee are financially literate and that Mr. Marks qualifies as an “audit committee financial expert” as defined by the Securities and Exchange Commission.
 
The committee assists the Board in fulfilling its oversight responsibilities relating to:
 
  
.
our auditing, accounting and reporting practices;
 
.
the adequacy of our systems of internal controls;
 
.
and the quality and integrity of publicly reported financial disclosures.
 
In this role, the committee appoints the independent auditors and reviews and approves the scope of the audit, the financial statements and the independent auditors’ fees.  The Audit Committee exercises the powers of the Board of Directors in connection with our accounting and financial reporting practices, and provides a channel of communication between the Board of Directors and independent registered public accountants.
 
Compensation Committee.
 
The Compensation Committee is comprised of three directors who meet the independence requirements of NASDAQ, are “non-employee directors” for purposes of Rule 16b-3 under the Securities Exchange Act of 1934 and are “outside directors” for purposes of Section 162(m) of the Internal Revenue Code. The purpose of our compensation committee is to discharge the responsibilities of our board of directors relating to compensation of our executive officers. Specific responsibilities of our compensation committee include: 

  
.

reviewing and recommending approval of compensation of our executive officers;

 
.

administering our stock incentive plan;

 
.

and reviewing and making recommendations to our board with respect to incentive compensation

 
 
and equity plans.


4. Code of Ethics and Business Conduct

At Jiangbo, we understand that good corporate governance and transparency is essential. We have adopted a Code of Ethics and Business Conduct to provide guiding principles to our officers, directors and employees. Our Code of Ethics and Business Conduct also strongly recommends that all directors and employees of our company comply with the code in the performance of their duties. Generally, our Code of Ethics and Business Conduct provides guidelines regarding:

  
.
compliance with laws, rules and regulations
 
.
conflicts of interest,
 
.
insider trading,
 
.
corporate opportunities
 
.
competition and fair dealing,
 
.
discrimination and harassment,
 
.
health and safety,
 
.
record-keeping,
 
.
confidentiality,
 
.
protection and proper use of company assets, and
 
.
payments to government personnel.



Copyright © 2008. All Rights Reserved